|
Title
|
|
|
|
Increased CSF -synuclein levels in Alzheimer's disease : correlation with tau levels
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Background Given the difficult clinical differential diagnosis between Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), growing interest resulted in research on α-synuclein as a potential cerebrospinal fluid biomarker (CSF) for synucleinopathies. Methods CSF α-synuclein-140 concentrations were determined by a prototype xMAP bead-based assay (Innogenetics NV, Belgium). In addition, CSF amyloid β1-42 (Aβ1-42), total tau (T-tau), and phosphorylated tau (P-tau181P) levels were determined. Results CSF α-synuclein levels were higher in AD patients as compared with cognitively healthy controls (P = .019) and patients with synucleinopathies (P < .001). CSF α-synuclein levels were correlated with T-tau (P < .001) and P-tau181P (P < .001) levels in autopsy-confirmed AD patients. A diagnostic algorithm using α-synuclein and P-tau181P discriminated neuropathologically confirmed AD from DLB patients, resulting in sensitivity and specificity values of 85% and 81%, respectively. Conclusion Because CSF α-synuclein levels were significantly higher in AD as compared with synucleinopathies, α-synuclein might have a value as a biomarker for differential dementia diagnosis. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Alzheimer's & dementia / Alzheimer’s Association [Chicago, Ill.] - Orlando, Fla, 2005, currens
|
|
|
Publication
|
|
|
|
Orlando, Fla
:
Elsevier
,
2014
|
|
|
ISSN
|
|
|
|
1552-5260
[print]
1552-5279
[online]
|
|
|
DOI
|
|
|
|
10.1016/J.JALZ.2013.10.004
|
|
|
Volume/pages
|
|
|
|
10
:5
(2014)
, p. 290-298
|
|
|
ISI
|
|
|
|
000366828100005
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|